MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-06-2026
Kamada Ltd. Operating Income 2011-2026 | KMDA
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Kamada Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.2 M | 20.1 M | 10.1 M | 4.53 M | -696 K | 19.2 M | 22.8 M | 19.3 M | 7.44 M | -5.48 M | -11.4 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 26.2 M | -11.4 M | 10.2 M |
Quarterly Operating Income Kamada Ltd.
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.2 M | 7.82 M | 7.07 M | 7.8 M | 20.1 M | 5.29 M | 5.64 M | 4.04 K | 10.1 M | 4.37 K | 2.63 M | 289 K | - | - | - | - | - | -804 K | - | - | - | 7.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 26.2 M | -804 K | 7.13 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-6.78 M | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 16.81 | -2.83 % | $ 786 M |  USA |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
13.7 B | - | - | $ 96.9 B |  Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
-76.3 M | $ 7.58 | -3.19 % | $ 208 M |  Israel |
 |
Athira Pharma
ATHA
|
-102 M | - | - | $ 269 M | USA |
 |
Galera Therapeutics
GRTX
|
-2.54 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-8.64 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 4.08 | -7.39 % | $ 1.22 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.61 | 1.26 % | $ 428 M | Britain |
 |
Compugen Ltd.
CGEN
|
31.3 M | $ 2.77 | -8.75 % | $ 259 M | Israel |
 |
BioNTech SE
BNTX
|
-1.4 B | $ 89.59 | -2.61 % | $ 21.7 B | Germany |
 |
Coherus BioSciences
CHRS
|
-181 M | $ 1.6 | -2.15 % | $ 187 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 3.43 | -3.65 % | $ 5.65 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-10.7 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-15 M | $ 0.72 | -2.32 % | $ 32.9 M | Israel |
 |
Esperion Therapeutics
ESPR
|
60.3 M | $ 3.13 | 0.16 % | $ 651 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Eton Pharmaceuticals
ETON
|
-844 K | $ 30.12 | -1.94 % | $ 810 M | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Exelixis
EXEL
|
872 M | $ 50.55 | -1.08 % | $ 13.7 B | USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 21.54 | -0.16 % | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Fortress Biotech
FBIO
|
-70.2 M | $ 2.39 | 3.91 % | $ 66.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
|
Forte Biosciences
FBRX
|
-70.7 M | $ 23.52 | -1.86 % | $ 305 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-6.28 M | $ 10.11 | 9.36 % | $ 289 M | USA |
 |
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M | USA |